巴瑞替尼治疗类风湿关节炎相关间质性肺病:文献综述与72例全国多中心研究
全国多中心回顾性研究纳入72例接受巴瑞替尼治疗的类风湿关节炎相关间质性肺病患者,中位随访32个月时呼吸困难、用力肺活量、一氧化碳弥散量和胸部高分辨率CT分别有90%、88%、65%和72%改善或稳定,DAS28-ESR由4.29降至2.99,泼尼松中位剂量由5 mg/天降至2.5 mg/天,相关不良事件不常见;作者认为巴瑞替尼可能是有用且安全的选择。
要点
- 中位随访32个月时呼吸困难90%、FVC 88%、DLCO 65%、HRCT 72%改善或稳定。
- DAS28-ESR由4.29降至2.99,泼尼松中位剂量由5 mg/天降至2.5 mg/天。
- 相关不良事件不常见,作者认为巴瑞替尼可能是有用且安全的选择。
核心结论
- 巴瑞替尼可能对类风湿关节炎相关间质性肺病患者的肺部与关节病变均为有用且安全的选择,即使对难治性病例亦然。
研究设计与样本
- 全国多中心回顾性研究,纳入72例接受巴瑞替尼治疗的类风湿关节炎相关间质性肺病患者。
- 在基线及3、6、12、18、24个月和末次随访时分析呼吸困难(改良医学研究委员会量表)、用力肺活量、一氧化碳弥散量、胸部高分辨率CT、DAS28-ESR和糖皮质激素节省效应。
- 分析安全性数据,并进行截至2023年12月的文献综述。
主要发现
- 纳入72例患者,其中女性52例,平均(标准差)年龄68(10)岁,全部患者均接受过改善病情抗风湿药。
- 至巴瑞替尼起始时,间质性肺病中位[四分位距]病程为25[13-63]个月;最常见类型为普通型间质性肺炎(n=33;49%)和非特异性间质性肺炎(n=22;32%)。
- 巴瑞替尼单药治疗43例(60%),联合传统合成改善病情抗风湿药29例(40%)。
- 基线的用力肺活量(%预计值)和一氧化碳弥散量(%预计值)平均(标准差)分别为86(28)和69(20)。
- 中位[四分位距]随访32[13-65]个月后,呼吸困难、用力肺活量、一氧化碳弥散量和胸部高分辨率CT分别有90%、88%、65%和72%改善或稳定;DAS28-ESR均值由4.29降至2.99,泼尼松中位剂量由5 mg/天降至2.5 mg/天。
关键数值与推荐
- 中位[四分位距]随访32[13-65]个月后,呼吸困难改善或稳定90%、用力肺活量改善或稳定88%、一氧化碳弥散量改善或稳定65%、胸部高分辨率CT改善或稳定72%。
- DAS28-ESR均值由4.29降至2.99。
- 泼尼松中位剂量由5 mg/天降至2.5 mg/天。
- 相关不良事件不常见。
临床怎么用
- 作者认为,巴瑞替尼可能对类风湿关节炎相关间质性肺病患者的肺部与关节病变均为有用且安全的选择,即使对难治性病例亦然。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to assess the effectiveness and safety of baricitinib (BARI) in interstitial lung disease associated with RA (RA-ILD) in clinical practice. METHODS: : This was a national multicentre retrospective study of 72 RA-ILD patients treated with BARI. We analysed the following outcomes at baseline and at 3, 6, 12, 18 and 24 months, and at last follow-up: (i) dyspnea (modified Medical Research Council scale), (ii) forced vital capacity (FVC), (iii) diffusing capacity of the lungs for carbon monoxide (DLCO), (iv) chest high-resolution CT (HRCT), (v) arthritis activity (DAS28-ESR), and (vi) CS-sparing effect. Additionally, we analysed the safety data and performed a literature review up to December 2023. RESULTS: We included 72 patients (52 women; mean (s.d.) age 68 (10) years). All patients had received DMARDs. The median [interquartile range (IQR)] ILD duration up to BARI initiation was 25 [13-63] months. The most frequent ILD patterns were usual interstitial pneumonia (n = 33; 49%) and non-specific interstitial pneumonia (n = 22; 32%). BARI was used in monotherapy in 43 (60%) patients and combined with conventional synthetic DMARDs in 29 (40%). Mean (s.d.) baseline values of FVC and DLCO (% predicted) were 86 (28) and 69 (20), respectively. After a median [IQR] follow-up of 32 [13-65] months, dyspnea, FVC, DLCO and HRCT improved or stabilized in 90%, 88%, 65% and 72%, respectively. The mean DAS28-ESR improved from 4.29 to 2.99, and the median prednisone dose was reduced from 5 to 2.5 mg/day. Relevant adverse events were uncommon. CONCLUSION: BARI may be a useful and safe alternative in both pulmonary and joint disease in RA-ILD patients, even in refractory cases.
引用
- Serrano-Combarro A, Atienza-Mateo B, Martín-Gutiérrez A, et al. Baricitinib in rheumatoid arthritis-interstitial lung disease: a literature review and national multicentre study of 72 patients. Rheumatology (Oxford). 2025. PMID: 40493905. doi:10.1093/rheumatology/keaf314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。